Chronic Graft Vs. Host DiseaseNCT05544032
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
A study testing axatilimab in people with Chronic Graft Vs. Host Disease, run by Incyte Corporation.
Trial summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Graft Vs. Host Disease
- What is being tested?
- axatilimab
- Type of treatment
- Injection or infusion
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Child, Adult, Older adult
Who may be able to join
- -
Who cannot join
- -
About this study
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
- Conditions
- Chronic Graft Vs. Host Disease
- Being tested
- axatilimab
- Keywords
- Chronic Graft Vs. Host Disease, cGVHD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
axatilimabDrug
Also called INCA34176
Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Graft Vs. Host DiseaseStudies of the same condition, open and under way.
- More trials run by Incyte CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Incyte Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05544032
- Sponsor's protocol ID
- I-34176-25-07
- Status last verified
- Jul 2026
- First submitted
- 14 Sep 2022
- Last updated
- 10 Jul 2026
- Results posted
- No